WO2009138094A1 - Pharmaceutical compositions - Google Patents
Pharmaceutical compositions Download PDFInfo
- Publication number
- WO2009138094A1 WO2009138094A1 PCT/EG2008/000017 EG2008000017W WO2009138094A1 WO 2009138094 A1 WO2009138094 A1 WO 2009138094A1 EG 2008000017 W EG2008000017 W EG 2008000017W WO 2009138094 A1 WO2009138094 A1 WO 2009138094A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- treatment
- liver
- liver cancer
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- liver cancer is the most commonly diagnosed cancer in Egypt as well as a leading cause of cancer death in males and females, ft is projected that in 2010 there will be about 2 millions new cases of live cancer diagnosed in Hgypt. And great number of deaths caused by liver cancer. Approximately 70% of the patients diagnosed with liver cancer have a form of the disease, which affect the liver. Liver cancer can metastasize to the skeletal s> stem and patients typically die with overwhelming osseous metastatic disease. As yet.
- tumor cell metastasis requires that cells depart from the primary tumor, invade the basement membrane, traverse through the bloodstream from tumor cell emboli, interact with the vascular endothelium of the target organ, extravasate. and proliferate to form secondary tumor colonies.
- Hepatitis viruses HCV and HBV the mostly responsible agents for lesions of cancer cell in liver.
- This treatment provide a simple type of therapy without need for the others chemotherapy
- Gene therapy is the one of the most recent trail for cancer therapy ,It depends on , and disease to treat a tissues and cells into an individual's genesinsertion of is replaced with a functional allele mutant in which a defective hereditary diseases one. Although the technology is still in its infancy, it has been used with some success.
- adenoviral vectors based upon a fundamental new understanding of the differences between cancerous and normal liver cells. The findings signal a new way to treat cancers that have spread to the liver, such as metastatic cancers of the colon and breast but there is not any enough proving that liver toxicity' is not an issue in gene therapy.
- Antisense therapy is not strictly a form of gene therapy, but is a genetically-mediated therapy and is often considered together with other methods.
- Nexavar is a 200 mg pill taken by mouth twice a day (2 tablets in the morning and 2 tablets at night on an empty Stomach). It is known as a kinase inhibitor. Nexavar works by interfering with molecules that may be linked to sending massages to cancer cells and by interfering in the formation of blood vessels that feed the cancer. Nexavar may also cause death of cancer cells. In clinical trials, patients who took Nexavar lived approximately 3 months longer than patients who took a placebo (dummy drug), and the liver tumor grew much slower in the patients taking Nexavar. This result was considered to be so beneficial that the study was discontinued and Nexavar was granted FDA approval.
- pancreatic enzymes as a new model for cancer eradication depend on that pancreas is a very important organ in the prevention of cancer. This is one reason diabetics get cancer more often than people with normal, functioning pancreases. It is theorized that with solid tumors, enzyme therapy slowly works to degrade the cell membranes of cancer cells, reducing growth and making other treatments more effective. Theoretically yes but the true depend on you must firstly understanding the cancer mechanism, not to destructed it only like the action of radiotherapy or the others chemotherapy.
- the present invention provides a Surprising discovery for liver cancer therapy. It comprises administering a first component, which contains the main regulator factor for the cell to return again to it's normal function and the second one enhance the immune cells to produce antibodies which reflect the level of consciousness of the immune cells for acceptance the power of anti cancer role.
- the present invention delivers magic therapeutic agents to a tumor using both targeting and pre-targeting methods to achieve effective and efficient delivery of the agents to the sites.
- the present invention provides a therapy method that addresses the problem of tumor heterogeneity by using multispecific targeting agents and by delivering at least three different therapeutic agents having different tumor-killing properties to the tumor sites.
- the present invention further provides a therapy method that minimizes patient toxicity caused by the therapeutic agents by using pre-targeting and targeting methods of delivery.
- the present invention additionally provides a therapy method with no toxic Effects on normal tissue.
- the present method of therapy specifically includes the following steps:
- this enzyme is the central enzyme in DNA replication and also serves an important role in DNA repair.
- (B) Administering to the patient a second component which is specific monoclonal antibodies for streptolysine antigen (Antistreptolysin Antibodies)
- the virus to support this mechanism he depleted all the polymerase activity contents of the cell, so there are marked accumulation for DNA damage and no repair for the DNA to return again for the cell original function .
- Imaging study chest x-ray, liver CT and abdominal sonography and satisfactory histological needle aspiration biopsy .
- compositions are preferably administered to an individual in a "therapeutically effective amount", this being sufficient to show benefit to the individual.
- the actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is ultimately within the responsibility and at the discretion of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners.
- the optimal dose can be determined by physicians based on a number of parameters including, for example, age, sex, weight, severity of the condition being treated, the active ingredient being administered and the route of administration.
- Treatment will consist of a course of 2 months we gave the patients the compositions two times daily the first component which is tag DNA polymerase enzyme in concentration 60 u/ul in 1 ml of tranexamic acid , 20 IU one times daily.
- the second injection 20 IU of monoclonal Abs where each injection daily contain 12 U/UI of tag DNA polymerase enzyme and 20 mg of tranexamic acid and 150 Todd of human monoclonal Abs (Antistreptolysin)
- compositions will be stored under sterile conditions at -20 C prior to use it is anticipated that in embodiments of the invention the compositions could not be given in combination with other forms of chemotherapy or indeed radiotherapy.
- Conjugates and compositions of and for use in the present invention may be administered to a patient in need of treatment via specific suitable route.
- Some suitable routes of administration include (but are not limited to) oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. Intravenous administration is preferred. It is envisaged that injections (subcutaneous or intramuscular) will be the primary route for therapeutic administration of compositions.
- liver of the patients return again for their normal functions without any need for chemotherapy, radiotherapy or liver surgery.
- compositions have a wide clinical use for the treatment of liver cancer; it is possible that some of these components may also enter clinical use for treatment of other cancer like colon cancer, kidney cysts , heart thrombosis and liver hepatitis C. these agents are associated with no particular side effects that may help physicians for using these agents in their clinics, the incidence of significant toxicities is relatively uncommon, and no side effects such as others anti-cancer agents.
Abstract
This invention for treatment of patients having lesions from cancer cells depend on replenish depleted intracellular polymerase enzyme, and enhancement the immune cells to attack cancerous cells with aiding of other clonal antibodies.
Description
Pharmaceutical compositions
Technical Field:
Anticancer therapeutic compositions for treatment of liver cancer Background Art :
The incidence of many forms of cancer is expected to increase with time. For example, liver cancer is the most commonly diagnosed cancer in Egypt as well as a leading cause of cancer death in males and females, ft is projected that in 2010 there will be about 2 millions new cases of live cancer diagnosed in Hgypt. And great number of deaths caused by liver cancer. Approximately 70% of the patients diagnosed with liver cancer have a form of the disease, which affect the liver. Liver cancer can metastasize to the skeletal s> stem and patients typically die with overwhelming osseous metastatic disease. As yet. there is no effective curative therapy and very little palliative therapy for patients with metastatic disease, fhe process of tumor cell metastasis requires that cells depart from the primary tumor, invade the basement membrane, traverse through the bloodstream from tumor cell emboli, interact with the vascular endothelium of the target organ, extravasate. and proliferate to form secondary tumor colonies.
It is generally accepted that Hepatitis viruses HCV and HBV the mostly responsible agents for lesions of cancer cell in liver.
This treatment provide a simple type of therapy without need for the others chemotherapy
Like putative anti-cancer drugs which are cytotoxic due to non- specific delivery of the drug resulting in toxic side effects to normal tissues. Therefore, in treating cancer, there is a need for a therapeutic approach that could enhance the established therapeutic qualities of putative anticancer substances while reducing their undesirable toxicity.
Gene therapy is the one of the most recent trail for cancer therapy ,It depends on , and disease to treat a tissues and cells into an individual's genesinsertion of is replaced with a functional allele mutant in which a defective hereditary diseases one. Although the technology is still in its infancy, it has been used with some success. Like using of gene therapy using adenoviral vectors, based upon a fundamental new understanding of the differences between cancerous and normal liver cells. The findings signal a new way to treat cancers that have spread to the liver, such as metastatic cancers of the colon and breast but there is not any enough proving that liver toxicity' is not an issue in gene therapy.
Antisense therapy is not strictly a form of gene therapy, but is a genetically-mediated therapy and is often considered together with other methods.
A major advance in the treatment of inoperable liver cancer was the approval of Nexavar by the FDA on November 19, 2007. Nexavar is a 200 mg pill taken by mouth twice a day (2 tablets in the morning and 2 tablets at night on an empty Stomach). It is known as a kinase inhibitor. Nexavar works by interfering with molecules that may be linked to
sending massages to cancer cells and by interfering in the formation of blood vessels that feed the cancer. Nexavar may also cause death of cancer cells. In clinical trials, patients who took Nexavar lived approximately 3 months longer than patients who took a placebo (dummy drug), and the liver tumor grew much slower in the patients taking Nexavar. This result was considered to be so beneficial that the study was discontinued and Nexavar was granted FDA approval.
But we consider Nexavar drug work for a short time to stoppage the cycle of cancer not for ever, also list of side effects, and include fatigue, weight loss, diarrhea and high blood pressure. Some patients developed a rash that consisted of skin shedding especially on their habds and feet; Nexavar is currently undergoing further studies for patients diagnosed with earlier stages only of liver cancer
Enzyme Therapy Pancreatic enzymes as a new model for cancer eradication depend on that pancreas is a very important organ in the prevention of cancer. This is one reason diabetics get cancer more often than people with normal, functioning pancreases. It is theorized that with solid tumors, enzyme therapy slowly works to degrade the cell membranes of cancer cells, reducing growth and making other treatments more effective. Theoretically yes but the true depend on you must firstly understanding the cancer mechanism, not to destructed it only like the action of radiotherapy or the others chemotherapy.
Disclosure of Invention:
The present invention provides a Surprising discovery for liver cancer therapy. It comprises administering a first component, which contains the main regulator factor for the cell to return again to it's normal function and the second one enhance the immune cells to produce antibodies which reflect the level of consciousness of the immune cells for acceptance the power of anti cancer role.
The present invention delivers magic therapeutic agents to a tumor using both targeting and pre-targeting methods to achieve effective and efficient delivery of the agents to the sites. The present invention provides a therapy method that addresses the problem of tumor heterogeneity by using multispecific targeting agents and by delivering at least three different therapeutic agents having different tumor-killing properties to the tumor sites.
The present invention further provides a therapy method that minimizes patient toxicity caused by the therapeutic agents by using pre-targeting and targeting methods of delivery.
The present invention additionally provides a therapy method with no toxic Effects on normal tissue.
The present method of therapy specifically includes the following steps:
(A) administering to the patient a first component which is tag DNA polymerase enzyme, a highly thermos table DNA polymerase of thermophilic bacterium thermus aquaticus
In concentration 5 u/UI, this enzyme is the central enzyme in DNA replication and also serves an important role in DNA repair.
(B) Administering to the patient a second component which is specific monoclonal antibodies for streptolysine antigen (Antistreptolysin Antibodies)
In concentration 800 todd/100 u, where this type of antibodies one of body defense when we infect by streptococcus haemolyticus bacterium antigen (Streptolysin Ag)
(C) Administering to the patients the third component which is tranexamic acid
Which has a good anti fibrinolytic mechanism to stop the process of the inflammation and prevent excessive fibrin degrade ate , we use it as a diluents for tag DNA polymerase enzyme in concentration 100 mg/ ImI.
To apply the present invention specially for HCC of the liver , We depend on mechanism of the viral hepatitis HCV in the liver cells ,this virus make the cell go I one directions and applied all orders for he virus with ought refuse ,this means the liver cell lose the power of anti -mechanism which make the cell still conscious .
The virus to support this mechanism he depleted all the polymerase activity contents of the cell, so there are marked accumulation for DNA damage and no repair for the DNA to return again for the cell original function .So we hypothesized that if we give the cell another source for polymerase enzyme from biological active bacterium cells, we can restore the damage DNA and solve the problem of DNA fragments accumulation within the cell to return fast to their normal function.
Other mechanism like HCV, we found it but his time in streptococcus haemolyticus bacterium; it secrete large amount of streptolysine antigen to destruct and lyses
Great amount of cell membranes and fibrin to make the inflammation persist for a long time, so this type of bacterium behave the same mechanism of HCV
For this we hypothesized that using the antibodies which our bodies produce as result of attacking by is antigen one of suitable method to stop the process of inflammation which considered the suitable conditions for cancer to grow up.
We combine the three components for treatment of liver cancer to exert the three effects for them.
Materials
Patients with well define focal lesions in the liver right or left lobe or both, splenomegally, ascitis.
Patients with advanced HCC and histologically confirmed cancer. All the patients have been explained to them that they have diagnosis with cancer and you understand that this treatment may increase your chances of living free from cancer.
And we told him about the combination treatment, the idea of the drug and the percentages of succeed, all of them concerning in participation of this study.
The patients conducted to pre treatment evaluations these parameters are a routine part of cancer patients work-up and follow up, complete history and physical examination including weight and height with an assessment of the patients performance status, routine laboratory study CBC with differential and platelets ,AFP , liver enzymes and albumin level
Imaging study chest x-ray, liver CT and abdominal sonography and satisfactory histological needle aspiration biopsy .
Dosage Regimen the compositions are preferably administered to an individual in a "therapeutically effective amount", this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is ultimately within the responsibility and at the discretion of general practitioners and other medical doctors, and typically takes account of the disorder to be treated, the condition of the individual patient, the site of delivery, the method of administration and other factors known to practitioners.
The optimal dose can be determined by physicians based on a number of parameters including, for example, age, sex, weight, severity of the condition being treated, the active ingredient being administered and the route of administration.
Treatment will consist of a course of 2 months we gave the patients the compositions two times daily the first component which is tag DNA polymerase enzyme in concentration 60 u/ul in 1 ml of tranexamic acid , 20 IU one times daily.
The second injection 20 IU of monoclonal Abs ,where each injection daily contain 12 U/UI of tag DNA polymerase enzyme and 20 mg of tranexamic acid and 150 Todd of human monoclonal Abs (Antistreptolysin)
The components will be stored under sterile conditions at -20 C prior to use it is anticipated that in embodiments of the invention the compositions could not be given in combination with other forms of chemotherapy or indeed radiotherapy.
Administration :
Conjugates and compositions of and for use in the present invention may be administered to a patient in need of treatment via specific suitable route.
Some suitable routes of administration include (but are not limited to) oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) administration. Intravenous administration is preferred.
It is envisaged that injections (subcutaneous or intramuscular) will be the primary route for therapeutic administration of compositions
Results :
The patients examined again after 2 months by ultrasonography, CT, histopathologically, and monitoring the values of liver enzymes, AFP the results for all patients complete disappearance of liver focal lesions, ascitis with normal caliber for portal vein and disappearance of P. V thrombosis
The liver of the patients return again for their normal functions without any need for chemotherapy, radiotherapy or liver surgery.
Conclusions :
The present invention compositions have a wide clinical use for the treatment of liver cancer; it is possible that some of these components may also enter clinical use for treatment of other cancer like colon cancer, kidney cysts , heart thrombosis and liver hepatitis C. these agents are associated with no particular side effects that may help physicians for using these agents in their clinics, the incidence of significant toxicities is relatively uncommon, and no side effects such as others anti-cancer agents.
Claims
Claims
1 -Anti-liver cancer component which is DNA polymerase as biological active enzyme. 2-Anti-liver cancer component which is monoclonal antibodies for streptolysin antigen. 3-Anti-liver cancer component which is tranexamic acid as anti-fϊbrinolytic agent.
4-The use of any one of Claim (1-2) alone or combined for treatment of liver cancer and other cancers in the body.
5- The use of DNA polymerase enzyme with concentration 5u/UI for treatment liver cancer and other cancers types.
6- The use of DNA polymerase enzyme with the previous concentration in claim (5) or others concentration for treatment liver cancer and other cancers types.
7- Compositions of the three components and the strategy of DNA polymerase enzyme for treatment of liver cancer and other cancers.
8-A method of liver cancer treatment with using DNA polymerase enzyme.
9-Use of DNA polymerase enzyme for treatment lesions of liver and others cancers.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EG2008/000017 WO2009138094A1 (en) | 2008-05-14 | 2008-05-14 | Pharmaceutical compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EG2008/000017 WO2009138094A1 (en) | 2008-05-14 | 2008-05-14 | Pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009138094A1 true WO2009138094A1 (en) | 2009-11-19 |
Family
ID=41318378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EG2008/000017 WO2009138094A1 (en) | 2008-05-14 | 2008-05-14 | Pharmaceutical compositions |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009138094A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111018739A (en) * | 2019-12-18 | 2020-04-17 | 中南大学湘雅三医院 | Tranexamic acid derivative, preparation method thereof and application thereof in preparation of drugs for treating oral cancer |
| CN115443130A (en) * | 2020-02-03 | 2022-12-06 | 传明科技有限责任公司 | Methods and compositions for treating diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6475996B1 (en) * | 1996-12-13 | 2002-11-05 | Centre National De La Recherche Scientifique (Cnrs) | Use of a vector expressing DNA polymerase β as medicine |
-
2008
- 2008-05-14 WO PCT/EG2008/000017 patent/WO2009138094A1/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6475996B1 (en) * | 1996-12-13 | 2002-11-05 | Centre National De La Recherche Scientifique (Cnrs) | Use of a vector expressing DNA polymerase β as medicine |
Non-Patent Citations (2)
| Title |
|---|
| CAI, J. ET AL.: "The radiobiologic characteristics of DNA polymerase beta in hepatomas] Zhonghua zhong liu za zhi", CHINESE JOURNAL OF ONCOLOGY], CHINA, vol. 18, no. 1, 1996, pages 20 - 22 * |
| FOSSÅ, S.D.: "Cyklokapron (tranexamic acid) in the treatment of patients with advanced neoplasms", TIDSSKRIFT FOR DEN NORSKE LAEGEFORENING : TIDSSKRIFT FOR PRAKTISK MEDICIN, NY RAEKKE, vol. 98, no. 28, 1978, NORWAY, pages 1368 - 1370 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111018739A (en) * | 2019-12-18 | 2020-04-17 | 中南大学湘雅三医院 | Tranexamic acid derivative, preparation method thereof and application thereof in preparation of drugs for treating oral cancer |
| CN115443130A (en) * | 2020-02-03 | 2022-12-06 | 传明科技有限责任公司 | Methods and compositions for treating diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Janson et al. | Octreotide and interferon alfa: a new combination for the treatment of malignant carcinoid tumours | |
| US5005588A (en) | Method for increasing tumor sensitivity to chemotherapy | |
| ES2409755T3 (en) | Method to Treat Cancer Using a Combined Anticancer Agent | |
| Chiu et al. | Synergistic antitumor effects of radiation and proteasome inhibitor treatment in pancreatic cancer through the induction of autophagy and the downregulation of TRAF6 | |
| CN107714684A (en) | Pharmaceutical composition and its application comprising α methyl DL tyrosine | |
| CN106659735A (en) | Pharmaceutical solution having anti-tumor effect-enhancing and toxicity-reducing effect, and pharmaceutical composition comprising same | |
| Bocci et al. | The clinical application of ozonetherapy | |
| Tsukamoto et al. | Subcutaneous Panniculitislike Tcell Lymphoma: Successful Initial Treatment with Prednisolone and Cyclosporin A | |
| Gumpel et al. | Synoviorthesis with erbium-169: a double-blind controlled comparison of erbium-169 with corticosteroid. | |
| WO2009138094A1 (en) | Pharmaceutical compositions | |
| Damyanov et al. | Low-dose chemotherapy with insulin (insulin potentiation therapy) in combination with hormone therapy for treatment of castration-resistant prostate cancer | |
| Leung et al. | PEGylated recombinant human arginase as a drug for breast cancer | |
| Goss et al. | DICE (dexamethasone, ifosfamide, cisplatin, etoposide) as salvage therapy in non-Hodgkin's lymphomas | |
| Dest | Radioprotectants: adding quality of life to survivorship? | |
| US20170173023A1 (en) | Combination therapy with volasertib | |
| Benetatos et al. | Rituximab as first line treatment for MALT lymphoma of extraocular muscles | |
| CN101073665B (en) | Use of lymphotoxin in treatment of medicine for increasing chemoradiotherapeutic sensitivity | |
| KR20220100006A (en) | Uses of multiple target protein kinase inhibitors | |
| CN100333797C (en) | Use of tumor treating of recombinant adenoviral P53 products | |
| RU2360712C1 (en) | Therapy of locally advanced nonresectable rectal cancer | |
| TW436287B (en) | Pharmaceutical composition for intramuscular administration comprising N-substituted benzamides, phenothiazines and their acid addition salts | |
| CN110613836A (en) | Compound medicine local injection preparation for treating liver cancer | |
| WO2017114215A1 (en) | Use of recombinant human calcineurin b subunit | |
| JPWO2014050912A1 (en) | Liquid medicine dissolved with carbon dioxide and therapeutic method using the same | |
| Santos et al. | Benefit of long-term adjunctive low-carbohydrate diet with intranasal perillyl alcohol therapy in the progression-free survival of a patient with glioblastoma: a case report and literature review |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08748835 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08748835 Country of ref document: EP Kind code of ref document: A1 |